The stock of Aratana Therapeutics Inc (NASDAQ:PETX) hit a new 52-week high and has $22.51 target or 119.00% above today’s $10.28 share price. The 5 months bullish chart indicates low risk for the $382.46 million company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $22.51 price target is reached, the company will be worth $455.13 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 2.33M shares traded hands or 231.39% up from the average. Aratana Therapeutics Inc (NASDAQ:PETX) has risen 186.24% since February 29, 2016 and is uptrending. It has outperformed by 174.02% the S&P500.
Analysts await Aratana Therapeutics Inc (NASDAQ:PETX) to report earnings on November, 3. They expect $-0.44 EPS, down 37.50% or $0.12 from last year’s $-0.32 per share. After $0.69 actual EPS reported by Aratana Therapeutics Inc for the previous quarter, Wall Street now forecasts -163.77% negative EPS growth.
Aratana Therapeutics Inc (NASDAQ:PETX) Ratings Coverage
Out of 6 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Aratana Therapeutics has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Lake Street initiated it with “Buy” rating and $28 target price in Wednesday, July 29 report. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) has “Overweight” rating given on Thursday, August 11 by Barclays Capital. The rating was initiated by Jefferies on Friday, August 19 with “Buy”. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) earned “Hold” rating by Craig Hallum on Friday, September 25. On Wednesday, March 16 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock has “Outperform” rating given by Credit Suisse on Thursday, February 4.
According to Zacks Investment Research, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.”
Insitutional Activity: The institutional sentiment increased to 1.59 in Q2 2016. Its up 0.47, from 1.12 in 2016Q1. The ratio increased, as 11 funds sold all Aratana Therapeutics Inc shares owned while 21 reduced positions. 12 funds bought stakes while 39 increased positions. They now own 30.25 million shares or 0.77% less from 30.49 million shares in 2016Q1.
Redmond Asset Limited Liability Com accumulated 0.17% or 53,472 shares. Parametric Portfolio Associates Limited Liability Company last reported 0% of its portfolio in the stock. State Board Of Administration Of Florida Retirement System has invested 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX). Vanguard holds 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 1.27 million shares. Kornitzer Cap Mngmt Ks last reported 0.02% of its portfolio in the stock. Alpinvest Bv has 100,001 shares for 1.25% of their US portfolio. Goldman Sachs Group Incorporated Inc holds 25,227 shares or 0% of its portfolio. Evercore Wealth Mngmt Limited Co owns 4,702 shares or 0% of their US portfolio. Westend Mngmt last reported 0.68% of its portfolio in the stock. Adams Asset Ltd Liability Corporation, a Texas-based fund reported 20,000 shares. Bridgeway Cap reported 86,983 shares or 0.01% of all its holdings. Dimensional Fund Lp reported 44,083 shares or 0% of all its holdings. Tiaa Cref Invest Lc accumulated 326,140 shares or 0% of the stock. Moreover, Morgan Stanley has 0% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 6,843 shares. Blackrock Inc has invested 0% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX).
Insider Transactions: Since June 10, 2016, the stock had 0 insider purchases, and 4 sales for $1.47 million net activity. Shares for $100,862 were sold by HEINEN ERNST on Friday, June 10. 100,000 shares with value of $626,313 were sold by St Peter Steven on Thursday, June 16. 30,000 shares were sold by TOOMAN CRAIG A, worth $277,599.
More notable recent Aratana Therapeutics Inc (NASDAQ:PETX) news were published by: Fool.com which released: “How Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August” on September 09, 2016, also Prnewswire.com with their article: “Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome …” published on June 30, 2016, Fool.com published: “Why Aratana Therapeutics Inc. Shares Crashed Today” on September 25, 2015. More interesting news about Aratana Therapeutics Inc (NASDAQ:PETX) were released by: Prnewswire.com and their article: “Aratana Therapeutics Reports First Quarter 2016 Financial Results” published on May 05, 2016 as well as Prnewswire.com‘s news article titled: “Aratana Therapeutics Files for Second FDA Approval” with publication date: March 22, 2016.
PETX Company Profile
Aratana Therapeutics, Inc., incorporated on December 1, 2010, is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Company’s product candidates also include AT-014 for dogs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.